Is Emergent BioSolutions Inc. (EBS) Overvalued?
We dive into why Emergent BioSolutions Inc. (EBS) could be considered overvalued on 2026-08-18, based on AAII’s Value Score and Grade.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Commentary & Analysis
4 Undervalued Biotechnology Stocks for Wednesday, August 12
Discover the top 4 undervalued Biotechnology stocks for Wednesday, August 12 based on AAII’s Stock Grades.Jenna Brashear
Why Emergent BioSolutions Inc.’s (EBS) Stock Is Down 6.71%
As of Monday, August 10, Emergent BioSolutions Inc.’s EBS share price has dipped by 6.71%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Emergent BioSolutions Inc.’s (EBS) Stock Is Down 24.01%
As of Thursday, August 06, Emergent BioSolutions Inc.’s EBS share price has dipped by 24.01%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Emergent BioSolutions Inc.’s (EBS) Stock Is Down 30.77%
As of Thursday, August 06, Emergent BioSolutions Inc.’s EBS share price has dipped by 30.77%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | EBS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $247.1 | $286.3 | 29% |
|
| Shares Out (Mil) | 51.6 | 54.2 | 48% |
|
| Institutional Ownership | 95.4% | 92.8% | 67% |
|
| Float (Mil) | 49.1 | 39.7 | 46% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 1,803 | 534 | 80% |
|
| Price Change (52-week) |
(47.6%) | 58.7% | 15% |
|
| Growth | EBS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (14.0%) | 13.6% | 4% |
|
| Net Income (5yr) | (29.7%) | (10.1%) | 14% |
|
| EPS (5yr) | (30.4%) | 16.0% | 8 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (25.9%) | (15.6%) | 24% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | na | |
| Current EPS | ($0.410) | $0.360 | $0.280 | |
| Month Ago EPS | $0.350 | $0.950 | na | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | $0.350 | $0.950 | na | |
| Year/Year Chg | (88.3%) | (61.3%) | na | |
| Financials | EBS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $770 | $37 | 47% |
|
| Net Income (TTM) (Mil) | ($177) | ($43) | 7% |
|
| EPS (TTM) | ($3.387) | ($1.400) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | $98 | ($31) | 52% |
|
| Net Cash Flow (TTM) (Mil) | ($130) | $2 | 12% |
|
| Long-Term Debt (Q1) (Mil) | $587 | $4 | 60% |
|
| Enterprise Value (Q1) (Mil) | na | $160 | na |
|
| Valuation | EBS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.72 | 2.77 | 13% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | EBS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 49.4% | 64.2% | 61% |
|
| Net Margin | (23.0%) | (75.9%) | 16% |
|
| ROA | (14.0%) | (47.3%) | 23% |
|
| ROE | (40.3%) | (55.0%) | 17% |
|
| Liabilities to Assets | 69.4% | 29.6% | 65% |
|
| F-Score | 5 | 2 | 50% |
|
Emergent BioSolutions Inc. did not pass any screens on 8/20/2026.
